Dynamic Diselenide Hydrogels for Controlled Tumor Organoid Culture and Dendritic Cell Vaccination

被引:0
|
作者
Han, Yueying [1 ]
Liu, Cheng [2 ]
Yin, Sheng [1 ]
Cui, Jian [1 ]
Sun, Yang [1 ]
Xue, Bin [1 ]
Jiang, Chunping [3 ,4 ]
Gu, Xiaosong [4 ]
Qin, Meng [1 ]
Wang, Wei [1 ]
Xu, Huaping [2 ]
Cao, Yi [1 ,4 ]
机构
[1] Nanjing Univ, Natl Lab Solid State Microstruct, Key Lab Intelligent Opt Sensing & Manipulat, Collaborat Innovat Ctr Adv Microstruct,Minist Educ, Nanjing 210093, Jiangsu, Peoples R China
[2] Tsinghua Univ, Dept Chem, Key Lab Organ Optoelect & Mol Engn, Beijing 100084, Peoples R China
[3] Nanjing Univ, Med Sch, Nanjing Drum Tower Hosp, Dept Hepatobiliary Surg,Affiliated Hosp, Nanjing 210008, Jiangsu, Peoples R China
[4] Jinan Microecol Biomed Shandong Lab, Jinan 250021, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
dynamic diselenide bonds; tumor organoids; free radical storm; DC-based vaccines; immunotherapy; 3-DIMENSIONAL CULTURE; ADHESION; CADHERIN;
D O I
10.1021/acsami.4c18728
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Dynamic hydrogels are emerging as advanced materials for engineering tissue-like environments that mimic cellular microenvironments. We introduce a diselenide-cross-linked hydrogel system with light-responsive properties, designed for precise control of tumor organoid growth and light-initiated radical inactivation, particularly for dendritic cell (DC) vaccines. Diselenide exchange enables stress relaxation and hydrogel remodeling, while recombination and quenching of seleno radicals (Se center dot) reduce cross-linking density, leading to controlled degradation. We demonstrate a 2D to 3D growth strategy, where tumor cells inoculate on the hydrogel surface, expand, and gradually form spherical organoids within the 3D hydrogel. These tumor organoids show significantly higher drug resistance compared to 2D-cultured cells. High-density light irradiation enhances diselenide exchange, inducing hydrogel degradation, tumor cell death, and release of functional antigens. This system serves as a dynamic platform for tumor organoid culture and antigen release, offering significantly advanced approaches for in vitro tumor modeling and immunological research. Our findings position diselenide-cross-linked hydrogels as versatile materials for precision cellular engineering, with broad applications in cancer research and beyond.
引用
收藏
页码:69114 / 69124
页数:11
相关论文
共 50 条
  • [41] Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination
    Aeyung Kim
    Young-Woock Noh
    Kwang Dong Kim
    Yong Suk Jang
    Yong-Kyung Choe
    Jong-Seok Lim
    Experimental & Molecular Medicine, 2004, 36 : 428 - 443
  • [42] Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
    Draube, Andreas
    Klein-Gonzalez, Nela
    Mattheus, Stefanie
    Brillant, Corinne
    Hellmich, Martin
    Engert, Andreas
    von Bergwelt-Baildon, Michael
    PLOS ONE, 2011, 6 (04):
  • [43] Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
    Olivier, T.
    Migliorini, D.
    REVUE NEUROLOGIQUE, 2023, 179 (05) : 502 - 505
  • [44] Surgery and adjuvant dendritic cell-based tumor vaccination for patients with relapsed malignant glioma
    Rutkowski, S
    De Vleeschouwer, S
    Kaempgen, E
    Wolff, JFA
    Soerensen, T
    Calenbergh, FA
    Van Gool, SW
    NEURO-ONCOLOGY, 2004, 6 (04) : 430 - 431
  • [45] Vaccination of cutaneous T-cell lymphoma patients with tumor lysate pulsed dendritic cells
    Maier, T
    Kyi, AT
    Dummer, R
    Burg, G
    Nestle, FO
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (03) : 756 - 756
  • [46] Vaccination of patients with metastatic renal carcinoma with dendritic Cell/Tumor Fusions following debulking nephrectomy
    Avigan, David
    Rosenblatt, Jacalyn
    Vasir, Baldev
    Atkins, Michael B.
    McDermott, David F.
    Lenahan, Corrine
    Wu, Zekui
    Bissonnette, Adam
    MacNamara, Claire
    Levine, James D.
    Uhl, Lynne
    Fitzgerald, Donna
    Lowe, Karen
    Dombagoda, Dilani
    Clancy, Myles
    Kufe, Donald
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 890 - 891
  • [47] Checkpoint inhibitor therapy after dendritic cell vaccination elicits tumor response in mesothelioma patients
    Cornelissen, Robin
    Belderbos, Robert
    Aerts, Joachim
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
    Garcia-Marquez, Maria A.
    Shimabukuro-Vornhagen, Alexander
    Theurich, Sebastian
    von Bergwelt-Baildon, Michael
    IMMUNOTHERAPY, 2013, 5 (10) : 1039 - 1042
  • [49] Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients
    Engleman, EG
    Fong, L
    CLINICAL IMMUNOLOGY, 2003, 106 (01) : 10 - 15
  • [50] Dynamic regulation of human dendritic cell precursor and subpopulations in the blood after yellow fever vaccination
    Winheim, E.
    Huang, Y.
    Eisenaecher, K.
    Scheck, M.
    Pritsch, M.
    Turan, A.
    Ahlfeld, J.
    Rothenfusser, S.
    Krug, A.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 133 - 133